{
    "Clinical Trial ID": "NCT00871858",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A (ANA)",
        "  Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.",
        "  anastrozole: Given orally",
        "INTERVENTION 2: ",
        "  Arm B (FULV)",
        "  Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.",
        "  fulvestrant: Given intramuscularly"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed invasive breast cancer, meeting 1 of the following criteria:",
        "  SBR grade I-II disease (patients < 65 years of age)",
        "  SBR grade I-III disease (patients > 65 years of age)",
        "  T2 (2-5 cm), T3, or T4B, and N0-1 disease",
        "  No metastatic disease",
        "  Breast lesion not amenable to breast-conserving resection",
        "  No inflammatory breast cancer",
        "  No prior breast cancer",
        "  Hormone receptor status:",
        "  Estrogen receptor- and/or progesterone receptor-positive",
        "  PATIENT CHARACTERISTICS:",
        "  Postmenopausal",
        "  No other cancer within the past 5 years except for adequately treated skin carcinoma or carcinoma in situ of the cervix",
        "  No contraindication to anti-hormonal treatment",
        "  No psychological, familial, social, or geographical reasons that would preclude follow up",
        "  PRIOR CONCURRENT THERAPY:",
        "  At least 8 days since prior hormone replacement therapy",
        "  No concurrent anti-vitamin K treatment"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Objective Response Rate (ORR) Determined by Clinical Palpation",
        "  Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.",
        "  Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).",
        "  Time frame: 6 months",
        "Results 1: ",
        "  Arm/Group Title: Arm A (ANA)",
        "  Arm/Group Description: Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.",
        "  anastrozole: Given orally",
        "  Overall Number of Participants Analyzed: 56",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  58.9        (45.0 to 71.9)",
        "Results 2: ",
        "  Arm/Group Title: Arm B (FULV)",
        "  Arm/Group Description: Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.",
        "  fulvestrant: Given intramuscularly",
        "  Overall Number of Participants Analyzed: 52",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  53.8        (39.5 to 67.8)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/60 (3.33%)",
        "  Bronchial infection 0/60 (0.00%)",
        "  Ankle fracture 1/60 (1.67%)",
        "  Clear cell kidney cancer 0/60 (0.00%)",
        "  Programmed peritoneal dialysis 1/60 (1.67%)",
        "  Endometrial atrophy 0/60 (0.00%)",
        "Adverse Events 2:",
        "  Total: 3/58 (5.17%)",
        "  Bronchial infection 1/58 (1.72%)",
        "  Ankle fracture 0/58 (0.00%)",
        "  Clear cell kidney cancer 1/58 (1.72%)",
        "  Programmed peritoneal dialysis 0/58 (0.00%)",
        "  Endometrial atrophy 1/58 (1.72%)"
    ]
}